Search results
Pfizer’s gene therapy for a muscle-wasting disorder misses main goal of late-stage study
WSAU Wausau· 3 days ago(Reuters) - Pfizer said on Wednesday its experimental gene therapy for a type of muscle-wasting...
Are Dividend Stocks The Best Source Of Passive Income? Here Are Three Alternative Options To...
Benzinga via Yahoo Finance· 22 hours agoPassive income is the dream for many investors, providing a steady stream of cash without the need...
Pfizer's Duchenne Muscular Dystrophy Treatment Misses Endpoints
Morningstar· 3 days agoPfizer's gene therapy being developed to treat Duchenne muscular dystrophy missed its primary endpoint in a late-stage trial. The pharmaceutical company said Wednesday the ...
Sarepta shares rise as Pfizer DMD trial misses goals By Investing.com
Investing.com· 2 days agoOn Thursday, Piper Sandler maintained an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT)...
KP.3 is the dominant COVID-19 variant in the US: Latest on test positivity, deaths, symptoms
USA Today· 2 days agoCases of the latest COVID-19 variant, also known as KP.3, are on the rise in the United States....
Spotlight on Pfizer: Analyzing the Surge in Options Activity - Pfizer (NYSE:PFE)
Benzinga· 5 days agoLoading... Loading... Whales with a lot of money to spend have taken a noticeably bearish stance on Pfizer . Looking at options history for Pfizer PFE we ...
After Federal Judge's Dismissal, Zantac Legal Fight Reignites in State Courts | Law.com
Law.com· 18 hours agoMore trials are planned in Illinois, California and Pennsylvania against the same drug...
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
Zacks via Yahoo Finance· 6 hours agoData from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved...
3 Ultra-High-Yield Dividend Stocks Billionaires Are Sinking Their Teeth Into
Motley Fool via Yahoo Finance· 2 days agoThis makes the single-digit forward price-to-earnings (P/E) ratios and high-yields attached to...
Lilly’s Weight-Loss Drug Is a Huge Hit. Its CEO Wants to Replace It ASAP.
The Wall Street Journal· 1 day agoThus far the sprint has been as fast as drug development can be, mainly between Lilly and Novo...